Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

  • STATUS
    Recruiting
  • participants needed
    40
  • sponsor
    Chongqing Precision Biotech Co., Ltd
Updated on 19 February 2024
remission
renal function
chemotherapy regimen
ejection fraction
stem cell transplantation
cell transplantation
multiple myeloma
mental disorders
oxygen saturation
refractory multiple myeloma
cellular therapy
bcma
cells therapy

Summary

This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.

Description

There are limited options for treatment of relapse/refractory Multiple Myeloma. BCMA is expressed on most Multiple Myeloma cells so it is an ideal target for CAR-T. In this study, investigators will evaluate the safety and efficacy of CAR-T targeting BCMA in patients with relapsed/refractory Multiple Myeloma. The primary goal is safety and efficiency assessment, including adverse events and disease status after treatment.

Details
Condition Plasma Cell Neoplasm, Multiple Myeloma, Multiple Myeloma, Lymphoproliferative Disorder, Multiple Myeloma in Relapse
Age 18years - 75years
Treatment BCMA CAR-T cells
Clinical Study IdentifierNCT04272151
SponsorChongqing Precision Biotech Co., Ltd
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Signed written informed consent
Diagnose as relapsed /refractory multiple myeloma, and meet one of the following
conditions
Failed to standard chemotherapy regimens
Relapse after complete remission, high-risk and / or refractory patients
Relapse after hematopoietic stem cell transplantation
Evidence for cell membrane BCMA expression
All genders, ages: 18 to 75 years
The expect time of survive is above 12 weeks
KPS60
No serious mental disorders
Left ventricular ejection fraction 50%
Sufficient hepatic function defined by ALT/AST3 x ULN and bilirubin2 x ULN
Sufficient renal function defined by creatinine clearance2 x ULN
Sufficient pulmonary function defined by indoor oxygen saturation92%
With single or venous blood collection standards, and no other cell collection contraindications
Ability and willingness to adhere to the study visit schedule and all protocol requirements

Exclusion Criteria

Have received CAR-T therapy or other genetically modified cell therapy before screening
Participated in other clinical research within 1 month before screening
Have received the following anti-tumor treatment before screening: Have received chemotherapy, targeted therapy or other experimental drug treatment within 4 weeks, except those who have confirmed disease progression after treatment
Live attenuated vaccine within 4 weeks before screening
Convulsion or stoke within past 6 months
Previous history of other malignancy
Presence of uncontrolled active infection
Subjects with positive HBsAg or HBcAb positive and peripheral blood HBV DNA titer is higher than the lower limit of detection of the research institution; HCV antibody positive and peripheral blood HCV RNA titer is higher than the lower limit of detection of the research institution; HIV antibody positive; syphilis primary screening antibody positive
Pregnant or breasting-feeding women
Any situation that investigators regard not suitable for attending in this study or may affect the data analysis
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.